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ndrea Mezzetti, MD,* Angela Falco, MD,* Tea Taraborelli, PHD,* Eleonora Devangelio, MD,*
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OBJECTIVES The goals of this study were to characterize the platelet contribution to soluble CD40 ligand
(sCD40L), to correlate its formation with the extent of oxidative stress and platelet activation,
and to investigate the effects of improved metabolic control and low-dose aspirin on these
processes.
BACKGROUND Inflammation, oxidative stress, and platelet activation are involved in the pathogenesis of type
2 diabetes (T2DM) and its complications. The CD40-CD40L interactions result in
inflammatory and pro-thrombotic responses.
METHODS Urinary 8-iso-prostaglandin (PG)F2 and 11-dehydro-thromboxane (TX)B2, in vivo markers
of oxidative stress and platelet activation, respectively, plasma CD40L, and C-reactive protein
(CRP) were measured in 114 T2DM patients and 114 control patients. A randomized,
parallel group, 17-day study of aspirin (30, 100, or 325 mg/day) was performed in 18 T2DM
patients. A similar study was performed in six healthy volunteers (aspirin, 100 mg/day).
Twenty poorly controlled T2DM patients were studied before and after improved metabolic
control.
RESULTS Compared with control patients, diabetic patients showed significantly higher levels of
8-iso-PGF2, 11-dehydro-TXB2, sCD40L, and CRP. On multiple regression analysis,
11-dehydro-TXB2 and 8-iso-PGF2 excretion rates predicted sCD40L levels. Soluble
CD40L linearly correlated with 11-dehydro-TXB2 (rho  0.67, p  0.0001), and both were
reduced after one week of aspirin (p  0.0026), with slow recovery over 10 days after aspirin
withdrawal. Improved metabolic control was associated with a reduction in sCD40L,
8-iso-PGF2, and 11-dehydro-TXB2.
CONCLUSIONS This study provides several lines of evidence for the dependence of sCD40L release on
TXA2-dependent platelet activation in T2DM and provides novel mechanistic insight into
the amplification loops of persistent platelet activation in this setting. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.0792006;47:391–7) © 2006 by the American College of Cardiology Foundation
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hhe strong correlation between type 2 diabetes mellitus
T2DM) and atherosclerosis suggests that both conditions
ay share a common background (1). A clustering of
ariables related to chronic low-grade inflammation, oxida-
ive stress, and platelet activation is emerging as a conceiv-
ble “common soil” that may influence the development of
oth diseases (2). We have previously reported biochemical
vidence of increased lipid peroxidation and persistent
latelet activation, as reflected by enhanced urinary excre-
ion of 8-iso-prostaglandin F2-alpha (8-iso-PGF2) and 11-
ehydro-thromboxane (TX)B2, respectively, in patients
ith T2DM: the excretion rates of these metabolites cor-
elated directly with metabolic control (3,4). Inflammatory
ytokines, adhesion molecules, and chemokines, although
nvolved in mediating all phases of atherothrombotic dis-
ases (5), have also been implicated in the development of
iabetes and its complications (6,7).
From the *Center of Excellence on Aging and Departments of Medicine and Drug
ciences, University of Chieti G. D’Annunzio Schools of Medicine and Pharmacy,
hieti, Italy; and the Departments of †Medical Therapy and ‡Pharmacology,
niversity of Rome La Sapienza, Rome, Italy. This study was supported by grants
rom the Italian Ministry of University and Research (FIRB) to the Center of
xcellence on Aging of the G. D’Annunzio University of Chieti.o
Manuscript received January 24, 2005; revised manuscript received March 3, 2005,
ccepted March 29, 2005.It is known that CD40 signaling mediates many inflam-
atory responses in atherosclerosis (8,9). A wide variety of
nflammatory cells express CD40 ligand (CD40L), and
timulation by other pro-inflammatory cytokines increases
ndothelial cell expression of CD40L (10). Up-regulation of
D40L at baseline prospectively predicts cardiovascular
vents among apparently healthy women (11). Elevated
oluble CD40L (sCD40L) levels have been found in both
ype 1 and 2 diabetes (12,13), further supporting the idea of
common basis for both diabetes and atherosclerosis (14).
Studies on the cellular distribution of CD40L indicate
hat 95% of the circulating sCD40L exists in platelets
15). These cells release pre-synthesized, stored functional
igand within seconds of activation in vitro and during
hrombus formation in vivo (15). Moreover, CD40 consti-
utively expressed on platelets provides a novel mechanism
or platelet activation (16). Platelets are likely to be major
ontributors to enhanced sCD40L in patients with acute
oronary syndromes (17), hypercholesterolemia (18), and
hronic inflammatory bowel disease (19). No study has so
ar investigated the cellular origin of the increased circulat-
ng sCD40L observed in diabetes. Thus, we tested the
ypothesis that the increased concentrations of sCD40L
bserved in T2DM may derive, at least in part, from
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CD40L and Platelet Activation in Type 2 Diabetes January 17, 2006:391–7XA2-dependent platelet activation. Therefore, the goals of
his study were to characterize the platelet contribution to
CD40L in T2DM, to correlate its formation with the
xtent of oxidative stress, and to investigate the effects of
mproved metabolic control and low-dose aspirin on these
rocesses.
ETHODS
atients. One-hundred and fourteen patients with T2DM
61 female, 53 male; mean age, 64.7 9.2 years), as defined
n accordance with the criteria of the American Diabetes
ssociation (20), and 114 age- and gender-matched healthy
ubjects were enrolled in the study. The baseline character-
stics of patients and control subjects are detailed in Table 1.
xclusion criteria were represented by a recent history (6
onths) of thrombotic event, pregnancy or delivery in the
revious six months, current medication for birth control or
ormone replacement therapy, regular use of antioxidants
vitamins C and E), non-steroidal anti-inflammatory drugs,
ntiplatelet agents, and iron treatment. Patients with cancer,
ecent infectious diseases, autoimmune disorders, renal in-
ufficiency or proteinuria (by serum creatinine levels and
rinalysis), altered hepatic function (by liver enzymes), or
lcohol abuse were also excluded.
Diabetic patients were examined for the presence of
icrovascular and macrovascular complications. Of the 114
atients, 13 (11%) had microvascular complications (10
ubjects had retinopathy, 3 had microalbuminuria). More-
ver, 26 had a history (6 months) or physical examination
Abbreviations and Acronyms
CRP  C-reactive protein
11-dehydro-TXB2  11-dehydro-thromboxane B2
HbA1c  hemoglobin A1c
IQR  interquartile range
8-iso-PGF2  8-iso-prostaglandin F2-alpha
LDL-C  low-density lipoprotein cholesterol
sCD40L  soluble CD40 ligand
T2DM  type 2 diabetes mellitus
TC  total cholesterol
able 1. Clinical Characteristics of Type 2 Diabetic Patients
nd Healthy Subjects
Variables
Type 2 Diabetes
Mellitus
(n  114)
Healthy
(n  114)
ender (female/male) 61/53 60/54
ge (yrs) 64.7  9.2 65.2  3
ody mass index kg/m2 24.4 24
iabetes duration (yrs) 11.85 —
asting blood glucose (mg/dl) 205.7  83.7 78.4  9.4
emoglobin A1c, % 8.2  1.6 3.6  0.8
ypertension, % 46.5 0
ypercholesterolemia, % 47 0
icrovascular complications, % 11 0sacrovascular complications, % 23 0ositive for evidence of macrovascular complications: 15
atients had stable angina pectoris, 5 had cerebrovascular
isease (transient ischemic attack or previous stroke), and 6
ad peripheral vascular disease. Patients with coronary heart
isease were in a stable phase. Patients with peripheral
ascular disease were in Fontaine stage II (intermittent
laudication, ankle-arm pressure index of 0.85, and no
esting pain). In none of the patients had vascular disease
ndergone detectable progression during the previous six
onths, as judged by clinical examination during out-
atient visits. At the time of the study, diabetic patients
ere being treated by diet alone (8 patients), insulin alone (3
atients), or by diet plus oral hypoglycemic agents (met-
ormin and/or sulfonylurea) (96 patients); in 7 patients,
nsulin was added to the oral hypoglycemic agents. Fifty-
hree patients had arterial hypertension, defined as current
ystolic/diastolic blood pressure 130/85 mm Hg. Fifty-
our patients were hypercholesterolemic (blood cholesterol
evel 200 mg/dl). Informed consent was obtained from
ach subject participating in the study. The local ethics
ommittee approved the protocol.
esign of the studies. In the first study, a cross-sectional
omparison of circulating sCD40L, urinary 8-iso-PGF2,
nd 11-dehydro-TXB2 was performed among all patients
nd controls. All subjects were studied as out-patients after
12-h fast and performed an overnight urine collection
mmediately before blood sampling. Urine samples were
dded with the antioxidant 4-hydroxy-tempo (1 mmol/l)
Sigma Chemical Co., St. Louis, Missouri) and stored at
20°C until extraction.
To assess the potential influence of improved metabolic
ontrol on sCD40L plasma levels, F2-isoprostane forma-
ion, and platelet activation, a second study was performed
n 20 of the 114 T2DM patients in whom inadequate
etabolic control had been achieved (fasting blood glucose
200 mg/dl, hemoglobin A1c [HbA1c] 8%) at the time
f the cross-sectional study, despite taking oral antidiabetic
gents for months. These patients were examined over a
our-week period with blood glucose monitoring, and oral
ntidiabetic therapy was adjusted accordingly and/or insulin
herapy was instituted to achieve improved metabolic con-
rol. Throughout the study, patients followed an isocaloric
iet that provided 50% of calories as carbohydrates, 30% as
at, and 20% as protein. The level of dietary cholesterol was
bout 0.3 g/day. Physical activity was encouraged, and
atients were instructed to walk at least 30 min after each
eal. No patient experienced a hypoglycemic reaction
uring the study period. Blood and overnight urine samples
ere obtained before and after this intensive metabolic
onitoring and treatment program for determination of
asting glucose and HbA1c levels, sCD40L, and urinary
-iso-PGF2 and 11-dehydro-TXB2.
To test the hypothesis of a platelet origin of sCD40L,
spirin (100 mg/day) was administered for one week to 6 of
he 114 T2DM patients. Overnight urine and fasting blood
amples were obtained before dosing and on the last day of
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January 17, 2006:391–7 CD40L and Platelet Activation in Type 2 Diabetesspirin treatment for measurement of circulating sCD40L,
rinary 8-iso-PGF2, and 11-dehydro-TXB2.
Based on the results obtained in this preliminary study,
e performed a randomized, parallel group study of three
ifferent doses of aspirin in 18 T2DM patients (10 female
nd 8 male; mean age, 60.7  6.1 years; body mass index,
9.4  4.4; diabetes duration, 14.7  7.1 years; fasting
lood glucose level, 148.9  39; HbA1c level, 7.8  1.1;
ypercholesterolemia, 66%; hypertension, 44%; microvascu-
ar complications, 22%; macrovascular complications, 5.5%).
his study included a one-week treatment period and a
0-day wash-out period. Patients were randomly assigned
o receive the following: aspirin, 30, 100, or 325 mg/day
Bayer, Milan, Italy). During the treatment period, each
atient took aspirin once daily at 9:00 AM. Moreover, during
his period, blood samples were collected at baseline, after
h, after 24 h, and on the 7th day. During the wash-out
eriod, blood samples (9:00 AM, after 12 h of fasting) were
ollected on the 3rd, 7th, and 10th day to characterize the
ime course of recovery of aspirin-induced biochemical
hanges. At each visit, blood samples were drawn for the
ollowing measurements: serum TXB2 obtained by incubat-
ng 1-ml whole blood samples for 1 h at 37°C (21) and
lasma sCD40L levels.
Finally, the same study was performed in six healthy
olunteers (4 female and 2 male; age 29.3  1.9 years) who
eceived aspirin 100 mg/day for one week. During the
reatment and wash-out periods, blood samples were col-
ected at the same times and with the same modalities used
or the 18 diabetic patients.
iochemical measurements. Fasting plasma glucose was
easured by the glucose oxidase method. The HbA1c level
as determined by automated high-performance liquid
hromatography (22). Total cholesterol (TC) and triglyc-
ride levels were determined by an enzymatic method;
igh-density lipoprotein cholesterol was measured after
hosphotungstic acid/MgCl2 precipitation on fresh plas-
a; low-density lipoprotein cholesterol (LDL-C) was
alculated by the Friedewald formula.
nzyme immunoassays. The sCD40L was determined by
nzyme-linked immunosorbent assay (R&D Systems, Min-
eapolis, Minnesota). Plasma C-reactive protein (CRP)
evels were measured with a highly sensitive immunoassay
23).
rinary eicosanoid assays. Urinary 8-iso-PGF2 and 11-
ehydro-TXB2 were measured by previously described ra-
ioimmunoassay methods (24,25). Measurements of urinary
-iso-PGF2 and 11-dehydro-TXB2 by these radioimmu-
oassays have been validated using different antisera and by
omparison with gas chromatography/mass spectrometry, as
etailed elsewhere (24,25).
tatistical analysis. With 114 subjects recruited in the
ross-sectional comparison, the study had 95% power to
etect a 40% difference in sCD40L serum levels between
he T2DM and control groups with a two-tailed  of 0.05. cThe data were analyzed by non-parametric methods to
void assumptions about the distribution of the measured
ariables. Comparisons between groups were made with the
ann-Whitney U test. Correlations were analyzed by the
pearman rank correlation test. A multiple linear regression
nalysis was performed to further quantify the relationship
etween sCD40L and the variables in study.
The intensive metabolic control and low-dose aspirin
tudies had an 80% power to detect a 20% and a 40%
hange, respectively, in plasma sCD40L levels. The differ-
nces between pre-intensive and post-intensive metabolic
ontrol were assessed by the Wilcoxon test. Data are
resented as mean (1 standard deviation) or as median and
nterquartile range (IQR) (25th, 75th percentile). Only p
alues 0.05 were regarded as statistically significant. All
ests were two-tailed, and analyses were performed using a
omputer software package (Statistica 1999 edition, Stat-
oft Inc., Tulsa, Oklahoma, or Statistical Package for the
ocial Sciences, version 11.0, SPSS Inc., Chicago, Illinois).
ESULTS
lasma CD40L levels were significantly higher in patients
ith T2DM than in age- and gender-matched healthy
atients (median [IQR]: 4.5 [2.3 to 7.9] ng/ml vs. 2.0 [1.4
o 3.1] ng/ml, p  0.0001). Plasma CRP levels were also
ignificantly increased in diabetic versus control patients
0.50 [0.30 to 1.0] mg/l vs. 0.36 [0.26 to 0.50] mg/l, p 
.0018).
The T2DM patients had a significantly higher urinary
-iso-PGF2 excretion rate in comparison with control
atients (median [IQR]: 316 (199 to 435) pg/mg vs. 190
150 to 269) pg/mg creatinine, p  0.0001) (Fig. 1).
rinary 11-dehydro-TXB2 excretion was also significantly
igher in diabetic patients compared with control patients
745 [477 to 1,531] pg/mg vs. 290 [206 to 467] pg/mg
reatinine, p  0.0001) (Fig. 1).
A significant direct correlation was found between plasma
D40L and 8-iso-PGF2 and 11-dehydro-TXB2 excretion
ates in diabetic patients (rho  0.55, p  0.0001, and rho
0.67, p  0.0001, respectively) (Fig. 2). Moreover, a
ignificant linear correlation was found between plasma
D40L and CRP levels (rho  0.43, p  0.0001).
The CRP was significantly related to 8-iso-PGF2 and
1-dehydro-TXB2 excretion rates in diabetic patients (rho
0.32, p  0.0004, and rho  0.455, p  0.0001,
espectively). Furthermore, a statistically significant corre-
ation was observed between urinary excretion of 8-iso-
GF2 and 11-dehydro-TXB2 (rho  0.62, p  0.0001).
To further define the relationship between sCD40L,
etabolic variables, additional atherosclerotic risk factors,
rinary prostanoid metabolites, and CRP, a multiple regres-
ion analysis was performed at baseline with sCD40L as the
ependent variable. Stepwise linear regression yielded a
odel in which only 11-dehydro-TXB2 (regression coeffi-ient  0.45, standard error of the mean  0.09, p 
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CD40L and Platelet Activation in Type 2 Diabetes January 17, 2006:391–7.0001) and 8-iso-PGF2 (regression coefficient  0.25,
tandard error of the mean  0.09, p  0.007) excretion
ates predicted sCD40L levels, independently of fasting
lood glucose, hypercholesterolemia, hypertension, presence
f macrovascular complications, and CRP. Thus, as shown
n Figure 2, among 43 diabetic patients with 11-dehydro-
XB2 and 8-iso-PGF2 excretion in the third and fourth
uartiles, 37 (86%) had increased levels of CD40L. In
ontrast, only 19% of T2DM patients with 11-dehydro-
XB2 and 8-iso-PGF2 urinary excretion in the first and
econd quartiles had increased levels of CD40L (p 
.0001).
nfluence of metabolic control on plasma CD40L
evels. Twenty patients with T2DM in whom adequate
etabolic control had not been achieved (HbA1c 8%)
ere subjected to intensive monitoring and treatment, and
igure 1. Box and whisker plots of urinary excretion of 11-dehydro-
hromboxane (TX)B2 (A), 8-iso-prostaglandin F2 (B), and plasma levels
f CD40L (C) in healthy patients and in type 2 diabetic patients. PG 
rostaglandin.lood samples were obtained before and after metabolic
fi
pontrol over four weeks. At the end of this period, the
edian HbA1c level decreased from 9.5% (range, 9.0% to
0.3%) to 7.0% (range, 7.0% to 8.0%) (p  0.0001).
mprovement in metabolic control was associated with a
ignificant reduction in CD40L levels (from 6.2 [range, 2.7
o 10.1] ng/ml to 4.2 [range, 2.5 to 5.8] ng/ml, p  0.003)
Fig. 3) and in both 8-iso-PGF2 (from 516 [range, 294 to
90] pg/mg to 318 [range, 143 to 609] pg/mg creatinine; p
0.0002) and 11-dehydro-TXB2 (from 1,360 [range, 930
o 2,172] pg/mg to 764 [range, 572 to 1,015] pg/mg
reatinine; p  0.0007) (Fig. 3) excretion. The CRP levels
ere not significantly affected by improved metabolic con-
rol (from 0.95 [range, 0.60 to 1.35] mg/l to 0.95 [range,
.50 to 1.20] mg/l, p  0.2959).
ffects of low-dose aspirin. Aspirin (100 mg/day) was
dministered for one week to 6 of the 114 T2DM patients.
t the end of this period, plasma CD40L decreased from
.1 1.1% to 4.7 1.3% (p 0.0026), with a concomitant
eduction in urinary 11-dehydro-TXB2 excretion (1,367 
81.3 pg/mg to 420  132 pg/mg creatinine; p  0.0001).
he CRP levels did not show any significant change after
spirin therapy (from 1  0.3 mg/l to 0.9  0.3 mg/l, p 
.69).
Based on the results obtained in this preliminary study,
e performed a randomized parallel group study of three
ifferent doses of aspirin in 18 T2DM patients in a 17-day
tudy. Plasma CD40L was significantly reduced after 2 h,
4 h, and 7 days of treatment with 30 mg, 100 mg, and 325
g of aspirin (Fig. 4) with no apparent dose effect. The
eduction in plasma CD40L at seven days averaged 53 
4%, 39  8%, and 52  11% after 30, 100, and 325 mg,
espectively. Whole-blood TXB2 production, a measure of
he maximum cyclooxygenase-dependent biosynthetic ca-
acity of blood platelets, was inhibited by 93  4%, 98 
%, and 99  1% seven days after 30, 100, and 325 mg of
spirin, respectively. The recovery of plasma CD40L levels
igure 2. Correlation between 8-iso-PGF2 and 11-dehydro-TXB2 excre-
ion rates in type 2 diabetic patients according to quartiles of plasma
D40L. Vertical and horizontal lines mark the boundaries of median
alues of both urinary metabolites. Open and closed circles represent
ndividual measurements, according to plasma CD40L: open circles 
rst and second quartile; solid circles  third and fourth quartile. PG 
rostaglandin; TX  thromboxane.
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January 17, 2006:391–7 CD40L and Platelet Activation in Type 2 Diabetesccurred slowly over the 10 days after aspirin withdrawal,
egardless of the aspirin dose.
Plasma CD40L was significantly reduced by 60  39%
fter 7 days of treatment with 100 mg aspirin in six healthy
olunteers (p  0.04), with a slow pattern of recovery over
he 10-day wash-out period (Fig. 5).
ISCUSSION
he CD40 ligand, a transmembrane protein structurally
elated to tumor necrosis factor-alpha, was originally iden-
ified on CD4 T cells, but it was also found on activated
latelets (15). Both membrane-bound and soluble forms of
his ligand may interact with CD40 expressed on vascular
ells, resulting in inflammatory responses (9). Platelets are
ajor contributors to enhanced sCD40L in patients with
cute coronary syndromes (17) and hypercholesterolemia
igure 3. Urinary excretion rates of 8-iso-prostaglandin F2 (A), 11-
ehydro-TXB2 (B), and plasma levels of CD40L (C) in 20 type 2 diabetic
atients before and after improved metabolic control. Both individual
easurements and box and whisker plots are shown. PG  prostaglandin;
X  thromboxane.18).
a
vEvidence of in vivo platelet activation has been previously
eported in diabetics (3,4), and increased plasma levels of
D40L have been described recently in both type 1 and
ype 2 diabetes mellitus (12,13). Moreover, significantly
ncreased co-expression of CD40 and CD40L on platelets
f diabetic patients compared with non-diabetic control
atients has been reported, with a significant correlation of
CD40L with CD40L expression on platelets (26). How-
igure 4. Time course of plasma CD40 levels before (time 0), during 7
ays of aspirin treatment (30, 100, and 325 mg/day, respectively), and at 3,
, and 10 days after aspirin withdrawal in 18 type 2 diabetic patients. Mean
1 standard deviation values are shown (n  6). *p  0.003 vs. baseline.
igure 5. Time course of plasma CD40 levels before (time 0), during 7
ays of aspirin treatment (100 mg/day), and at 3, 7, and 10 days after
spirin withdrawal in 6 healthy volunteers. Mean  1 standard deviation
alues are shown (n  6). *p  0.004 vs. baseline.
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CD40L and Platelet Activation in Type 2 Diabetes January 17, 2006:391–7ver, the contribution of persistent platelet activation to
ncreased shedding of CD40L has not been previously
nvestigated.
In the present study, the highly significant correlation
etween plasma CD40L levels and the urinary excretion
ate of 11-dehydro-TXB2, a non-invasive index of in vivo
latelet activation (4) (Fig. 2), supports the likelihood of
D40L release during TXA2-dependent platelet activation
n T2DM. This relationship is in keeping with previously
eported evidence showing that CD40L is rapidly up-
egulated during platelet activation (15) and that platelet
D40 itself provides a mechanism for platelet activation
16). The contribution of platelets to enhanced CD40L
elease in T2DM is strengthened by the observation that
oth improved metabolic control and low-dose aspirin, two
ndependent interventions down-regulating platelet activa-
ion in this setting, significantly reduced plasma CD40L
evels without any measurable impact on systemic inflam-
ation, as reflected by the non-significant change in CRP
lasma levels.
In addition, we found a positive correlation between
nhanced sCD40L and 8-isoPGF2, in line with the recent
eport of increased production of endothelial reactive oxy-
en species by CD40L (27), suggesting that in T2DM the
elease of sCD40L from activated platelets may contribute
o increased oxidant stress. Increased lipid peroxidation and
ersistent platelet activation have previously been reported
n patients with T2DM (3,4). Thus, our findings suggest a
ossible vicious cycle in which inflammatory stimuli induce
ncreased lipid peroxidation with consequent platelet acti-
ation, resulting in further oxidant stress (15).
To further characterize the platelet origin of plasma
D40L, we investigated the dose- and time-dependence of
he effects of aspirin in T2DM. Low-dose aspirin is able to
educe TXA2-dependent platelet activation in several clin-
cal settings (28), and a recent report indicates that platelet-
erived interleukin-1-beta is down-regulated by low-dose
spirin in hypercholesterolemia (29). Thus, we performed
n open pilot study and then a randomized dose-response
tudy with aspirin (30, 100, and 325 mg) in T2DM patients.
atients’ compliance was verified by the profound suppres-
ion of TXB2 production during whole-blood clotting.
lasma CD40L levels were significantly reduced by 40% to
0% at any aspirin dose, indicating that TXA2-dependent
echanisms are responsible, at least in part, for CD40L
elease by platelets: in fact, the r2 value for the linear
elationship between TXA2-dependent platelet activation
nd CD40L levels was 0.45 in the present study. Both the
aturability of the effect of aspirin at low doses and the
ime-dependent pattern of recovery of plasma CD40L levels
n aspirin withdrawal are consistent with an effect depen-
ent on platelet cyclooxygenase-1 inactivation (30). More-
ver, the lack of a dose-effect in the 30 to 325 mg range
rgues against an anti-inflammatory effect of the drug
ontributing to the reduction in plasma CD40L.
t
The aspirin study in T2DM raises the question of
hether only 40% to 50% of plasma CD40L is TXA2-
ependent, or the enhanced release of CD40L observed in
2DM is largely TXA2-dependent but cannot be further
educed below normal levels. To address this question, we
erformed an additional study in six healthy volunteers, who
ere administered aspirin (100 mg/day) for 7 days, and their
ime course of plasma CD40L levels over 17 days was
haracterized. The similar reduction in plasma sCD40L
evels within the normal range, as well as the similar
ime-course of recovery, strongly supports the hypothesis
hat in the setting of T2DM, both TXA2-dependent and
independent mechanisms of platelet activation contribute
o enhanced release of sCD40L.
Previous results obtained from volunteer donors before
nd after seven days of aspirin (325 mg/day) showed a 50%
ecrease in sCD40L release measured ex vivo from platelet
ggregates stimulated with collagen, a platelet agonist de-
endent on TXA2 production (31). However, the latter
tudy presents two main limitations: first, the choice of a
25 mg/day dose, together with the lack of any information
bout the time course of recovery of plasma CD40L levels
n aspirin withdrawal, does not allow exclusion of an impact
f aspirin on systemic inflammation, which could influence
er se sCD40L levels; second, this experiment was per-
ormed ex vivo in a quite artificial milieu reproducing
ollagen stimulation. Conversely, our results clearly show
hat low-dose aspirin is able to down-regulate sCD40L
roduction in vivo both in diabetic and in healthy subjects.
These findings may have therapeutic implications for
therothrombotic disease. Previously, the studies by Linde-
ann et al. (32) and by May et al. (33) showed that
nhibition of glycoprotein IIb/IIIa engagement markedly
ttenuated the synthesis of platelet interleukin-1-beta and
D40L, respectively. Because platelet inflammatory medi-
tors, such as interleukin-1-beta and CD40L, might trigger
igure 6. Role of CD40L in the biochemical mechanisms linking hyper-
lycemia, inflammation, lipid peroxidation, and platelet activation. Poten-
ial amplification loops sustaining this chain of events are also shown. PG
prostaglandin; sCD40L  soluble CD40 ligand; TX  thromboxane.
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o atherogenesis, matrix degradation, and plaque rupture
8), prevention by antiplatelet agents of platelet cytokine
elease may contribute to their cardioprotective effects.
We conclude that persistent platelet activation is respon-
ible for increased levels of sCD40L in T2DM. Because
ow-dose aspirin can only incompletely down-regulate this
henomenon, we suggest that additional antiplatelet strat-
gies should be investigated in an attempt to interrupt the
icious circle triggered by sCD40L-mediated events in this
etting (Fig. 6).
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